| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AGTRAP |
| Uniprot No | Q6RW13 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-159aa |
| 氨基酸序列 | MELPAVNLKVILLGHWLLTTWGCIVFSGSYAWANFTILALGVWAVAQRDSIDAISMFLGGLLATIFLDIVHISIFYPRVSLTDTGRFGVGMAILSLLLKPLSCCFVYHMYRERGGELLVHTGFLGSSQDRSAYQTIDSAEAPADPFAVPEGRSQDARGY |
| 预测分子量 | 17,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AGTRAP重组蛋白的3篇示例参考文献(注：文献为示例性概括，具体内容可能需要根据实际研究调整)：
---
1. **文献名称**：*"AGTRAP modulates angiotensin II receptor signaling by recruiting protein phosphatase 1"*
**作者**：Wu et al.
**摘要**：研究发现重组AGTRAP蛋白通过与AT1受体结合，招募蛋白磷酸酶1(PP1)，抑制血管紧张素II介导的ERK磷酸化，从而调控下游细胞增殖和炎症反应。
2. **文献名称**：*"Recombinant AGTRAP expression in HEK293 cells: A tool for functional characterization"*
**作者**：Zhang et al.
**摘要**：本文建立了在HEK293细胞中高效表达重组AGTRAP蛋白的方法，并通过免疫共沉淀验证其与AT1受体的相互作用，为研究其在高血压病理中的调控机制提供工具。
3. **文献名称**：*"AGTRAP attenuates angiotensin II-induced cardiac fibrosis via suppressing NADPH oxidase activation"*
**作者**：Li et al.
**摘要**：通过动物模型和重组蛋白实验，揭示AGTRAP通过抑制NADPH氧化酶活性，减轻血管紧张素II诱导的心脏纤维化，提示其作为潜在治疗靶点。
---
**注**：以上文献信息为模拟示例，实际引用时请核实真实存在的论文及作者信息。建议通过PubMed或Google Scholar以关键词“AGTRAP recombinant”“AGTRAP angiotensin receptor”检索最新研究。
AGTRAP (Angiotensin II Receptor-Associated Protein) is a regulatory protein closely linked to the renin-angiotensin system (RAS), which plays a central role in cardiovascular homeostasis, blood pressure regulation, and fluid balance. Discovered as an interacting partner of the angiotensin II type 1 receptor (AT1R), AGTRAP modulates AT1R signaling by promoting receptor internalization and degradation, thereby influencing cellular responses to angiotensin II, a key peptide in RAS activation. This interaction highlights its potential role in mitigating excessive AT1R-mediated effects, such as vasoconstriction, inflammation, and tissue remodeling, which are implicated in hypertension, heart failure, and kidney diseases.
Recombinant AGTRAP protein is engineered using expression systems like *E. coli* or mammalian cells to produce purified, functional protein for research and therapeutic exploration. Its production enables detailed studies of AGTRAP’s structure-function relationships, post-translational modifications, and mechanisms in RAS signaling. Researchers utilize recombinant AGTRAP to investigate its regulatory effects on AT1R trafficking, its interplay with other RAS components (e.g., ACE2. Mas receptor), and its potential as a biomarker or therapeutic target in cardiovascular and metabolic disorders.
Emerging evidence suggests AGTRAP may also intersect with non-canonical pathways, including oxidative stress and cell proliferation, expanding its relevance to diabetes, cancer, and fibrosis. However, its precise physiological and pathological roles remain incompletely understood, partly due to tissue-specific expression patterns and complex feedback loops within RAS. Recombinant AGTRAP tools are critical for unraveling these complexities, offering insights into RAS modulation strategies and paving the way for novel interventions in diseases driven by RAS dysregulation. Challenges persist in optimizing protein stability, activity, and delivery for translational applications.
×
